Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic strategy for managing metabolic disorders. These naturally occurring molecules are secreted by the gut in response to food intake, stimulating insulin release and suppressing glucagon secretion. GLP-1 agents demonstrate promising therapeutic results in treating type 2